ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
40 announcements
Bliss GVS Pharma Ltd reported the voting results of its postal ballot. Members approved the appointment of Mr. Santosh Parab as a Non-Executive and Non-Independent Director.
Bliss GVS Pharma allotted equity shares under its Employee Stock Option Scheme (ESOP). This increases the company's total paid-up share capital.
Bliss GVS Pharma allotted 55,250 equity shares under its Employee Stock Option Plan 2019 at an exercise price of Rs. 43 per share.
Anupam Rasayan India Ltd completed an open offer to acquire 26% of Bliss GVS Pharma Ltd. Only 1,669 shares were acquired for ₹4.99 Lakh.
Bliss GVS Pharma Ltd issued a Postal Ballot Notice to seek shareholder approval for the appointment of Mr. Santosh Parab as a Director.
Bliss GVS Pharma Ltd reported revenue from operations of ₹285.6 Cr (+37.6% YoY) and net profit of ₹51.4 Cr (+15.8% YoY) for Q1 FY27.
Bliss GVS Pharma Ltd has allotted 31,250 equity shares to eligible employees under its ESOP 2019 scheme. This action increases the company's total paid-up share capital.
Life Insurance Corporation of India reduced its stake in Bliss GVS Pharma Ltd by 2.15% via market sale. The institutional investor's holding decreased to 2.96%.
Bliss GVS Pharma Ltd will hold a board meeting on August 12, 2026. The board will consider and approve financial results for the quarter ended June 30, 2026.
Bliss GVS Pharma Ltd announced the resignation of Mr. Sachin Saboo, General Manager – Regulatory & Clinical, effective from the close of business hours on July 24, 2026.
Bliss GVS Pharma is transferring unclaimed dividends from 2018-2019 and related shares to the IEPF. Shareholders are notified to claim these funds by October 27, 2026.
Clarus Trust acquired an additional 0.18% stake in Bliss GVS Pharma via open market purchases, taking their total holding to 5.13%.
Anupam Rasayan India Ltd has launched an open offer to acquire up to 2.77 crore shares of Bliss GVS Pharma at ₹299 per share.
Bliss GVS Pharma Ltd received an addendum to the open offer's public announcement, adding Mates Visa Consultancy Pvt Ltd as a Person Acting in Concert.
Bliss GVS Pharma concluded its 41st AGM on July 15, 2026. Shareholders approved a 100% final dividend of Re. 1.00 per share for FY 2025-26.
Bliss GVS Pharma updated contact details for KMPs authorized to determine and report material events. This administrative update ensures compliance with SEBI LODR Regulation 30(5).
Bliss GVS Pharma allotted ESOP shares, increasing paid-up capital. No monetary value disclosed; share count rose from 106.06M to 106.24M.
Bliss GVS Pharma allotted 1,87,750 shares under its ESOP plan. The share capital increased to Rs. 10,62,43,972 after this allotment.
Bliss GVS Pharma appointed Rahul Adakmol as CEO, effective July 15, 2026. Narsimha Shibroor Kamath stepped down as CEO but remains Managing Director.
Bliss GVS Pharma allotted 2,67,250 equity shares under its ESOP 2019 to employees. The move increases paid-up capital and aligns employee interests with shareholders.
Anupam Rasayan announced a ₹829.03 Crore open offer for Bliss GVS Pharma. The acquirer seeks a 26% stake following a controlling share purchase agreement.
Bliss GVS Pharma received a WHO-GMP Inspection Closure Report for its Palghar manufacturing facility. This certification confirms compliance with international quality standards for pharmaceutical manufacturing.
Promoter Gagan Harsh Sharma sold 2,17,123 shares of Bliss GVS Pharma Limited via the open market. This transaction reduced his individual holding to nil.
Anupam Rasayan India Limited launched an ₹805.12 Crore open offer to acquire a 26% stake in Bliss GVS Pharma Limited. The offer price is set at ₹299 per share.
Anupam Rasayan India Limited launched an ₹829.03 Crore open offer for Bliss GVS Pharma. The offer follows a 43.30% stake acquisition, aiming for a majority 69.51% holding.
Bliss GVS Pharma submitted its Annual Secretarial Compliance Report for FY2026. The report details governance adherence and provides updates on previous regulatory non-compliance matters.
Mr. Santosh Parab completed his final term as Independent Director on May 25, 2026. This planned leadership change follows statutory term limits for independent directors.
Anupam Rasayan India Limited is acquiring a 43.30% stake in Bliss GVS Pharma for ₹1,369.51 Crore. The deal triggers a mandatory 26% open offer.
Anupam Rasayan launched a ₹829.03 Crore open offer to acquire a 26% stake in Bliss GVS Pharma. This follows a majority acquisition trigger via agreement.
Promoter Punita Sharma sold 24,962 shares of Bliss GVS Pharma via the open market. This transaction reduces the seller's individual stake to zero.